Key Highlights

● Absci rose sharply alongside Schrodinger and Recursion.

● No company-specific news explained the gain.

● The move came amid a broader AI infrastructure rally.

● Twist Bioscience, Tempus AI and 10x Genomics also rose.

Absci (NASDAQ:ABSI) jumped as a group of stocks tied to AI-driven drug discovery rallied together. The stock rose sharply in intraday trading, moving alongside Schrodinger and Recursion Pharmaceuticals, with no company news found to explain any of the three moves.

The only release from Absci that day was a routine notice that it would attend upcoming investor conferences, which does not typically move a stock on its own.

A Sector-Wide Move

Stocks in a narrow theme often trade as a pack, and the rally spread beyond the core group, with Twist Bioscience, Tempus AI and 10x Genomics also rising on no specific news. The move came on a strong day for the broader AI trade, with Vertiv and Oracle both soaring and chip stocks rising for a fourth straight session.

Absci combines generative AI with laboratory biology to design antibodies and other protein-based drugs, developing its own programs while also partnering with pharmaceutical companies.

A Narrow but Positive Tape

The Federal Reserve left its benchmark rate range unchanged, with two officials dissenting in favor of a hike. Long-dated Treasury yields climbed, typically a headwind for speculative growth stocks, making the strength in early-stage biotech names stand out.

Breadth was narrow across the broader market, a sign that gains were concentrated in a limited set of stocks even as the small-cap Russell 2000 advanced.